Animal study · mice and rats
Amycretin cut body weight by 18% in obese rats over 21 days
Checked against the paper Animal studyPublished by PepVault
The takeaway
This is early animal work showing amycretin lowered food intake and weight and improved insulin sensitivity in rats, and improved fatty liver in rodents; it does not show these effects in people.
- Kind
- Animal study
- Studied in
- Mice and rats
- Published
- 2025
- Journal
- EBioMedicine
What they tested
The team wanted to see whether amycretin, a single molecule that acts on both GLP-1 and amylin receptors, could ease diet-driven obesity, insulin resistance and fatty liver in mice and rats.
How the study was done
A preclinical study in diet-induced obese rats and in mice, with cell-based tests of GLP-1, amylin and calcitonin receptors. In the main rat work, amycretin was given for 21 days and compared with vehicle, an inactive control.

Model. Individual results vary.
What they found
In cell-based tests, amycretin switched on human, mouse and rat GLP-1, amylin and calcitonin receptors. In diet-induced obese rats, 21 days of amycretin lowered total energy intake by 47% and body weight by 18% compared with vehicle (p < 0.0001), and energy expenditure stayed the same. In mice, it reached brain areas that control food intake, and in the obese rats, insulin sensitivity improved on a hyperinsulinemic euglycemic clamp (a test of how much glucose must be infused to keep blood sugar steady while insulin is high). In this mouse and rat work, amycretin also improved signs of MASLD (fatty liver disease) on liver tissue, mostly through less fat buildup in the liver.
What it doesn’t show
These are mouse, rat and cell results, not results in people, and the main treatment lasted only 21 days. The study was funded by Novo Nordisk A/S.
The paper
Kuhre et al. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine. 2025.
The compound
More studies on Amycretin
- Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeksRandomized trial · people · 2026
- Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetesRandomized trial · people · 2026
- Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trialRandomized trial · people · 2025
- Amycretin: side effects all mild or moderate in first human trialRandomized trial · people · 2025
- Amycretin: similar drug exposure with kidney impairment in phase 1Clinical trial · people · 2026
- Every study on Amycretin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.